FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010640916> ?p ?o ?g. }

• W2010640916 endingPage "84" @default.
• W2010640916 startingPage "77" @default.
• W2010640916 abstract "To determine the maximum-tolerated dose (MTD) of irinotecan and paclitaxel in this two-drug combination, and to investigate a sequence-dependent effect in the pharmacokinetics of these drugs, we conducted a phase I study in chemo-naïve patients with advanced non-small cell lung cancer (NSCLC).Patients with stage IIIB/IV NSCLC were enrolled in this study. Both irinotecan and paclitaxel were administered on days 1 and 8, and repeated every 3 weeks. The starting dose of both drugs was 40 mg/m2 which was then alternately increased by 10 mg/m2 increments. In the first cycle, irinotecan was initially administered and followed by paclitaxel infusion, while the sequence of drug administration was reversed in the second cycle. Blood samples for pharmacokinetic analysis were obtained on day 1 of the first and second cycles.Nine patients received a total of 12 cycles, which were evaluated for toxicity and efficacy. The main hematological toxicity was neutropenia. Grades 3 or more neutropenia was observed in 67% of cycles at dose level 2. The main non-hematological toxicities were grade 3 febrile neutropenia, supraventricular arrhythmia, and grade 2 hepatic dysfunction. The MTD of irinotecan and paclitaxel were 40 and 50 mg/m2, respectively. In the pharmacokinetic analysis, the maximum concentration of paclitaxel was elevated in a dose-dependent manner. There was a trend toward elevation of the area under the plasma concentration-time curve (AUC) of irinotecan and a decline of the AUC of paclitaxel in cycle 1 (irinotecan followed by paclitaxel), compared with those in cycle 2 (paclitaxel followed by irinotecan). Hepatic toxicity was strongly associated with the AUC of irinotecan (r = 0.894, P < 0.0001). The objective response was not observed in the nine patients.The combination of irinotecan and paclitaxel with this schedule produced considerable toxicities without any antitumor effect for advanced NSCLC. The different schedule of administration or other combinations should be investigated." @default.
• W2010640916 created "2016-06-24" @default.
• W2010640916 creator A5006348007 @default.
• W2010640916 creator A5007888883 @default.
• W2010640916 creator A5012161478 @default.
• W2010640916 creator A5025271372 @default.
• W2010640916 creator A5039723911 @default.
• W2010640916 creator A5056477482 @default.
• W2010640916 creator A5062920555 @default.
• W2010640916 creator A5066700160 @default.
• W2010640916 creator A5067650050 @default.
• W2010640916 creator A5070015883 @default.
• W2010640916 creator A5074862416 @default.
• W2010640916 date "2004-07-01" @default.
• W2010640916 modified "2023-09-27" @default.
• W2010640916 title "A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer" @default.
• W2010640916 cites W1502025781 @default.
• W2010640916 cites W1594148627 @default.
• W2010640916 cites W1816481860 @default.
• W2010640916 cites W1934698255 @default.
• W2010640916 cites W1935885922 @default.
• W2010640916 cites W1942035808 @default.
• W2010640916 cites W1970465987 @default.
• W2010640916 cites W1992039369 @default.
• W2010640916 cites W2031750715 @default.
• W2010640916 cites W2040211532 @default.
• W2010640916 cites W2055600926 @default.
• W2010640916 cites W2059055591 @default.
• W2010640916 cites W2079123814 @default.
• W2010640916 cites W2080847559 @default.
• W2010640916 cites W2092979462 @default.
• W2010640916 cites W2125367921 @default.
• W2010640916 cites W2139248078 @default.
• W2010640916 cites W2140543434 @default.
• W2010640916 cites W2162062930 @default.
• W2010640916 cites W2504684570 @default.
• W2010640916 doi "https://doi.org/10.1016/j.lungcan.2004.01.001" @default.
• W2010640916 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15196737" @default.
• W2010640916 hasPublicationYear "2004" @default.
• W2010640916 type Work @default.
• W2010640916 sameAs 2010640916 @default.
• W2010640916 citedByCount "9" @default.
• W2010640916 countsByYear W20106409162017 @default.
• W2010640916 countsByYear W20106409162018 @default.
• W2010640916 crossrefType "journal-article" @default.
• W2010640916 hasAuthorship W2010640916A5006348007 @default.
• W2010640916 hasAuthorship W2010640916A5007888883 @default.
• W2010640916 hasAuthorship W2010640916A5012161478 @default.
• W2010640916 hasAuthorship W2010640916A5025271372 @default.
• W2010640916 hasAuthorship W2010640916A5039723911 @default.
• W2010640916 hasAuthorship W2010640916A5056477482 @default.
• W2010640916 hasAuthorship W2010640916A5062920555 @default.
• W2010640916 hasAuthorship W2010640916A5066700160 @default.
• W2010640916 hasAuthorship W2010640916A5067650050 @default.
• W2010640916 hasAuthorship W2010640916A5070015883 @default.
• W2010640916 hasAuthorship W2010640916A5074862416 @default.
• W2010640916 hasBestOaLocation W20106409162 @default.
• W2010640916 hasConcept C112705442 @default.
• W2010640916 hasConcept C121608353 @default.
• W2010640916 hasConcept C126322002 @default.
• W2010640916 hasConcept C143998085 @default.
• W2010640916 hasConcept C2776256026 @default.
• W2010640916 hasConcept C2776694085 @default.
• W2010640916 hasConcept C2777063308 @default.
• W2010640916 hasConcept C2777292972 @default.
• W2010640916 hasConcept C2778850193 @default.
• W2010640916 hasConcept C2780259306 @default.
• W2010640916 hasConcept C29730261 @default.
• W2010640916 hasConcept C526805850 @default.
• W2010640916 hasConcept C71924100 @default.
• W2010640916 hasConcept C90924648 @default.
• W2010640916 hasConcept C98274493 @default.
• W2010640916 hasConceptScore W2010640916C112705442 @default.
• W2010640916 hasConceptScore W2010640916C121608353 @default.
• W2010640916 hasConceptScore W2010640916C126322002 @default.
• W2010640916 hasConceptScore W2010640916C143998085 @default.
• W2010640916 hasConceptScore W2010640916C2776256026 @default.
• W2010640916 hasConceptScore W2010640916C2776694085 @default.
• W2010640916 hasConceptScore W2010640916C2777063308 @default.
• W2010640916 hasConceptScore W2010640916C2777292972 @default.
• W2010640916 hasConceptScore W2010640916C2778850193 @default.
• W2010640916 hasConceptScore W2010640916C2780259306 @default.
• W2010640916 hasConceptScore W2010640916C29730261 @default.
• W2010640916 hasConceptScore W2010640916C526805850 @default.
• W2010640916 hasConceptScore W2010640916C71924100 @default.
• W2010640916 hasConceptScore W2010640916C90924648 @default.
• W2010640916 hasConceptScore W2010640916C98274493 @default.
• W2010640916 hasIssue "1" @default.
• W2010640916 hasLocation W20106409161 @default.
• W2010640916 hasLocation W20106409162 @default.
• W2010640916 hasLocation W20106409163 @default.
• W2010640916 hasLocation W20106409164 @default.
• W2010640916 hasOpenAccess W2010640916 @default.
• W2010640916 hasPrimaryLocation W20106409161 @default.
• W2010640916 hasRelatedWork W1970649592 @default.
• W2010640916 hasRelatedWork W2010640916 @default.
• W2010640916 hasRelatedWork W2055244776 @default.
• W2010640916 hasRelatedWork W2055600926 @default.

• next